Addendum
Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114
Report documents
-
Addendum
Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114
Dossier assessment
Indication:
Adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy
Result of dossier assessment:
Unchanged after addendum: hint of minor added benefit
Additional information
Federal Joint Committee (G-BA)
2023-04-06 A G-BA decision was published.
Project details
- Project no.
- A23-12
- Commission
- Commission awarded on 21.02.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V
Status: Commission completed